Author:
Brittain R T,Boutal L,Carter M C,Coleman R A,Collington E W,Geisow H P,Hallett P,Hornby E J,Humphrey P P,Jack D
Abstract
Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, ([1 alpha (Z), 2 beta,5 alpha]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4-heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference68 articles.
1. UNSTABLE METABOLITES OF ARACHIDONIC ACID AND THEIR ROLE IN HAEMOSTASIS AND THROMBOSIS
2. Thromboxanes and ischaemic vascular disease;Hornstra G;Neth J Med,1982
3. Prostacyclin and Blood Coagulation
4. Coleman RA Collington EW Geisow HP Hornby EJ Humphrey PPA Kennedy 1 Levy GP Lumley P McCabe PJ Wallis CJ: AH19437 a specific thromboxane receptor blocking drug? Br J Pharmacol 72: 524P 1981
5. Further evidence that AH 19437 is a specific thromboxane receptor blocking drug;Coleman RA;Br J Pharmacol,1981
Cited by
93 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献